News headlines about Evolent Health (NYSE:EVH) have trended somewhat positive on Tuesday, according to Accern. Accern scores the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Evolent Health earned a coverage optimism score of 0.24 on Accern’s scale. Accern also assigned press coverage about the technology company an impact score of 44.7533772394244 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the media headlines that may have impacted Accern’s scoring:

Shares of Evolent Health (NYSE:EVH) traded down 1.86% during trading on Tuesday, reaching $15.80. 1,425,715 shares of the company were exchanged. Evolent Health has a 1-year low of $14.50 and a 1-year high of $27.50. The company’s 50-day moving average is $17.30 and its 200 day moving average is $17.30. The firm’s market capitalization is $1.04 billion.

Evolent Health (NYSE:EVH) last announced its earnings results on Monday, August 7th. The technology company reported ($0.13) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.13). The company had revenue of $107.30 million during the quarter, compared to the consensus estimate of $104.45 million. Evolent Health had a negative net margin of 17.57% and a negative return on equity of 6.44%. Evolent Health’s revenue was up 89.9% compared to the same quarter last year. During the same period last year, the firm earned ($0.20) earnings per share. Equities research analysts expect that Evolent Health will post ($0.40) EPS for the current fiscal year.

Several equities analysts have recently issued reports on EVH shares. Jefferies Group LLC reiterated a “buy” rating and set a $28.00 target price on shares of Evolent Health in a report on Wednesday, September 6th. KeyCorp started coverage on shares of Evolent Health in a report on Tuesday, September 19th. They set an “overweight” rating and a $23.00 target price for the company. Robert W. Baird reiterated an “outperform” rating and set a $25.00 target price (down from $35.00) on shares of Evolent Health in a report on Tuesday, September 26th. They noted that the move was a valuation call. Cowen and Company reiterated an “outperform” rating and set a $35.00 target price on shares of Evolent Health in a report on Wednesday, June 28th. Finally, BidaskClub lowered shares of Evolent Health from a “buy” rating to a “hold” rating in a report on Monday, July 31st. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $28.45.

TRADEMARK VIOLATION WARNING: This article was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.watchlistnews.com/evolent-health-evh-given-news-impact-rating-of-0-24/1637325.html.

In other Evolent Health news, COO Thomas Peterson III sold 40,540 shares of the firm’s stock in a transaction that occurred on Monday, July 24th. The shares were sold at an average price of $26.00, for a total value of $1,054,040.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Frank J. Williams sold 16,300 shares of the firm’s stock in a transaction that occurred on Thursday, August 3rd. The shares were sold at an average price of $23.73, for a total transaction of $386,799.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 62,840 shares of company stock valued at $1,588,679. 8.79% of the stock is owned by insiders.

About Evolent Health

Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.

Insider Buying and Selling by Quarter for Evolent Health (NYSE:EVH)

Receive News & Ratings for Evolent Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.